{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:59:47Z","timestamp":1791993587929,"version":"4.4.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This study highlights the significance of supercharged NK (sNK) cells in inducing the lysis and differentiation of tumors at much higher levels compared to primary activated NK cells. sNK cells-induced higher release of growth factors, cytokines, and chemokines when compared to primary activated NK cells. When we used a similar level of IFN-\u03b3 from primary activated NK cells and sNK cells, the IFN-\u03b3 secreted from sNK cells exhibited greater potential to induce differentiation in both oral and pancreatic tumors. It is long known in the field of NK cells that primary NK cells induce significant lysis of stem-like\/poorly differentiated tumors, but differentiated tumors are generally resistant to primary NK cell-mediated lysis. sNK cells, unlike primary activated NK cells, are found to highly target stem-like as well as differentiated tumors, indicating sNK cells can target not only tumors specific to NK cells but also those targeted by CD8+ T cells. Differentiation by sNK cells was inhibited less by the antibodies to IFN-\u03b3 and TNF-\u03b1 when compared to that mediated by the primary activated NK cells, suggesting the role of other unexplored mechanisms in sNK cell-induced tumor differentiation. Overall, this study suggests the role of sNK cells in targeting the heterogeneous population of tumors, likely mediating the functions of both NK cells and T cells in controlling tumors, and inducing them to be effectively targeted by chemotherapy.<\/jats:p>","DOI":"10.1038\/s41419-025-07986-2","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T11:55:15Z","timestamp":1756727715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Supercharged NK cells: a unique population of NK cells capable of differentiating stem cells and lysis of MHC class I high differentiated tumors"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1936-5985","authenticated-orcid":false,"given":"Kawaljit","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahid","family":"Jewett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"7986_CR1","doi-asserted-by":"publisher","first-page":"537","DOI":"10.7150\/jca.15989","volume":"8","author":"AK Kozlowska","year":"2017","unstructured":"Kozlowska AK, Topchyan P, Kaur K, Tseng HC, Teruel A, Hiraga T, et al. Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells\/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs. J Cancer. 2017;8:537\u201354.","journal-title":"J Cancer"},{"key":"7986_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.semcancer.2018.08.001","volume":"53","author":"A Jewett","year":"2018","unstructured":"Jewett A, Kos J, Fong Y, Ko MW, Safaei T, Peri\u0161i\u0107 Nanut M, et al. NK cells shape pancreatic and oral tumor microenvironments; role in inhibition of tumor growth and metastasis. Semin Cancer Biol. 2018;53:178\u201388.","journal-title":"Semin Cancer Biol"},{"key":"7986_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.coi.2018.03.022","volume":"51","author":"K Kaur","year":"2018","unstructured":"Kaur K, Nanut MP, Ko MW, Safaie T, Kos J, Jewett A. Natural killer cells target and differentiate cancer stem-like cells\/undifferentiated tumors: strategies to optimize their growth and expansion for effective cancer immunotherapy. Curr Opin Immunol. 2018;51:170\u201380.","journal-title":"Curr Opin Immunol"},{"key":"7986_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fimmu.2017.00297","volume":"8","author":"K Kaur","year":"2017","unstructured":"Kaur K, Cook J, Park S-H, Topchyan P, Kozlowska A, Ohanian N. et al. Novel strategy to expand super-charged NK cells with significant potential to lyse and differentiate cancer stem cells: differences in NK expansion and function between healthy and cancer patients. Front Immunol. 2017;8:297","journal-title":"Front Immunol"},{"key":"7986_CR5","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097\u2013100.","journal-title":"Science"},{"key":"7986_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1056\/NEJMoa1200503","volume":"367","author":"JM Venstrom","year":"2012","unstructured":"Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N. Engl J Med. 2012;367:805\u201316.","journal-title":"N. Engl J Med"},{"key":"7986_CR7","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00262-010-0904-3","volume":"59","author":"EG Iliopoulou","year":"2010","unstructured":"Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2010;59:1781\u20139.","journal-title":"Cancer Immunol Immunother"},{"key":"7986_CR8","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051\u20137.","journal-title":"Blood"},{"key":"7986_CR9","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/cncr.22002","volume":"107","author":"F Re","year":"2006","unstructured":"Re F, Staudacher C, Zamai L, Vecchio V, Bregni M. Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors. Cancer. 2006;107:640\u20138.","journal-title":"Cancer"},{"key":"7986_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3109\/14653249.2010.515582","volume":"13","author":"MA Geller","year":"2011","unstructured":"Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13:98\u2013107.","journal-title":"Cytotherapy"},{"key":"7986_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023;23:90\u2013105.","journal-title":"Nat Rev Immunol"},{"key":"7986_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03437-0","volume":"20","author":"J Chu","year":"2022","unstructured":"Chu J, Gao F, Yan M, Zhao S, Yan Z, Shi B, et al. Natural killer cells: a promising immunotherapy for cancer. J Transl Med. 2022;20:240.","journal-title":"J Transl Med"},{"key":"7986_CR13","doi-asserted-by":"publisher","first-page":"9521","DOI":"10.3390\/ijms24119521","volume":"11","author":"F Portale","year":"2023","unstructured":"Portale F, Di Mitri D. NK. Cells in cancer: mechanisms of dysfunction and therapeutic potential. Int J Mol Sci. 2023;11:9521","journal-title":"Int J Mol Sci"},{"key":"7986_CR14","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41423-021-00808-3","volume":"19","author":"F Fang","year":"2022","unstructured":"Fang F, Xie S, Chen M, Li Y, Yue J, Ma J, et al. Advances in NK cell production. Cell Mol Immunol. 2022;19:460\u201381.","journal-title":"Cell Mol Immunol"},{"key":"7986_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-76702-1","volume":"10","author":"K Kaur","year":"2020","unstructured":"Kaur K, Ko MW, Ohanian N, Cook J, Jewett A. Osteoclast-expanded super-charged NK-cells preferentially select and expand CD8+ T cells. Sci Rep. 2020;10:20363.","journal-title":"Sci Rep"},{"key":"7986_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1615\/CritRevImmunol.2020033391","volume":"40","author":"A Jewett","year":"2020","unstructured":"Jewett A, Kos J, Kaur K, Turnsek TL, Breznik B, Senjor E, et al. Multiple defects of natural killer cells in cancer patients: anarchy, dysregulated systemic immunity, and immunosuppression in metastatic cancer. Crit Rev Immunol. 2020;40:93\u2013133.","journal-title":"Crit Rev Immunol"},{"key":"7986_CR17","doi-asserted-by":"publisher","first-page":"20002","DOI":"10.18632\/oncotarget.4755","volume":"6","author":"HC Tseng","year":"2015","unstructured":"Tseng HC, Kanayama K, Kaur K, Park SH, Park S, Kozlowska A, et al. Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation. Oncotarget. 2015;6:20002\u201325.","journal-title":"Oncotarget"},{"key":"7986_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood-2009-11-255026","volume":"116","author":"H Li","year":"2010","unstructured":"Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood. 2010;116:210\u20137.","journal-title":"Blood"},{"key":"7986_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3389\/fimmu.2015.00576","volume":"6","author":"VT Bui","year":"2015","unstructured":"Bui VT, Tseng HC, Kozlowska A, Maung PO, Kaur K, Topchyan P, et al. Augmented IFN-\u03b3 and TNF-\u03b1 induced by probiotic bacteria in NK cells mediate differentiation of stem-like tumors leading to inhibition of tumor growth and reduction in inflammatory cytokine release; regulation by IL-10. Front Immunol. 2015;6:576.","journal-title":"Front Immunol"},{"key":"7986_CR20","doi-asserted-by":"publisher","first-page":"e1426518","DOI":"10.1080\/2162402X.2018.1426518","volume":"7","author":"K Kaur","year":"2018","unstructured":"Kaur K, Topchyan P, Kozlowska AK, Ohanian N, Chiang J, Maung PO, et al. Super-charged NK cells inhibit growth and progression of stem-like\/poorly differentiated oral tumors in vivo in humanized BLT mice; effect on tumor differentiation and response to chemotherapeutic drugs. Oncoimmunology. 2018;7:e1426518.","journal-title":"Oncoimmunology"},{"key":"7986_CR21","doi-asserted-by":"publisher","first-page":"63.","DOI":"10.3390\/cancers12010063","volume":"12","author":"K Kaur","year":"2019","unstructured":"Kaur K, Kozlowska AK, Topchyan P, Ko MW, Ohanian N, Chiang J. et al. Probiotic-treated super-charged NK cells efficiently clear poorly differentiated pancreatic tumors in Hu-BLT mice. Cancers. 2019;12:63.","journal-title":"Cancers"},{"key":"7986_CR22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1017\/S0007114511005824","volume":"108","author":"H Dong","year":"2012","unstructured":"Dong H, Rowland I, Yaqoob P. Comparative effects of six probiotic strains on immune function in vitro. Br J Nutr. 2012;108:459\u201370.","journal-title":"Br J Nutr"},{"key":"7986_CR23","doi-asserted-by":"publisher","first-page":"1132807.","DOI":"10.3389\/fimmu.2023.1132807","volume":"14","author":"K Kaur","year":"2023","unstructured":"Kaur K, Chen P-C, Ko M-W, Mei A, Senjor E, Malarkannan S, et al. Sequential therapy with supercharged NK cells with either chemotherapy drug cisplatin or anti-PD-1 antibody decreases the tumor size and significantly enhances the NK function in Hu-BLT mice. Front Immunol. 2023;14:1132807.","journal-title":"Front Immunol"},{"key":"7986_CR24","doi-asserted-by":"crossref","unstructured":"Sadeghi S, Chen P-C, Jewett A, Kaur K. Chapter 14 - Combination of NK cell immunotherapy with chemotherapy and radiation enhances NK cell therapy and provides improved prognosis in cancer patients and in humanized BLT mouse model system. In: Jewett A, Fong Y, editors. NK cells in cancer immunotherapy: successes and challenges. Academic Press; pp. 301\u201320, 2023.","DOI":"10.1016\/B978-0-12-822620-9.00022-7"},{"key":"7986_CR25","doi-asserted-by":"crossref","unstructured":"Senjor E, Ko M-W, Kaur K, Chen P-C, Breznik B, Chovatiya N, et al. Chapter 1 - Multifaceted nature of natural killer cells: potential mode of interaction and shaping of stem cells. In: Jewett A, Fong Y, editors. NK cells in cancer immunotherapy: successes and challenges. Academic Press; pp. 3\u201325, 2023.","DOI":"10.1016\/B978-0-12-822620-9.00020-3"},{"key":"7986_CR26","doi-asserted-by":"crossref","unstructured":"Ko M-W, Kaur K, Chen P-C, Breznik B, Senjor E, Chovatiya N, et al. Chapter 13 - Diagnostic methods to assess the numbers, phenotype, and function of primary and engineered NK cells: methods to predict prognosis and treatment outcome. In: Jewett A, Fong Y, editors. NK cells in cancer immunotherapy: successes and challenges. Academic Press; pp. 281\u201397, 2023.","DOI":"10.1016\/B978-0-12-822620-9.00013-6"},{"key":"7986_CR27","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00262-021-03044-w","volume":"71","author":"K Kaur","year":"2022","unstructured":"Kaur K, Ko M-W, Chen F, Jewett A. Defective NK cell expansion, cytotoxicity, and lack of ability to differentiate tumors from a pancreatic cancer patient in a long term follow-up: implication in the progression of cancer. Cancer Immunol, Immunother. 2022;71:1033\u201347.","journal-title":"Cancer Immunol, Immunother"},{"key":"7986_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/cancers13020239","volume":"13","author":"K Kaur","year":"2021","unstructured":"Kaur K, Safaie T, Ko M-W, Wang Y, Jewett A. ADCC against MICA\/B is mediated against differentiated oral and pancreatic and not stem-like\/poorly differentiated tumors by the NK cells; loss in cancer patients due to down-modulation of CD16 receptor. Cancers. 2021;13:239.","journal-title":"Cancers"},{"key":"7986_CR29","doi-asserted-by":"crossref","unstructured":"Jewett A, Kos J, Turnsek TL, Chen P-C, Breznik B, Senjor E, et al. Chapter 6 - Novel strategies to expand supercharged NK cells with augmented capacity to withstand inactivation by tumors. In: Bonavida B, Jewett A, editors. Successes and challenges of NK immunotherapy. Academic Press; pp. 101\u201319, 2021.","DOI":"10.1016\/B978-0-12-824375-6.00005-9"},{"key":"7986_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevImmunol.2021037163","volume":"41","author":"K Kaur","year":"2021","unstructured":"Kaur K, Ko M-W, Chen P-C, Breznik B, Senjor E, Wong P. et al. Probiotics in health and disease: distinct roles of different strains in natural killer cell activation and regulation. Crit Rev Immunol. 2021;41:1\u201319.","journal-title":"Crit Rev Immunol"},{"key":"7986_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.omto.2019.11.002","volume":"16","author":"A Jewett","year":"2020","unstructured":"Jewett A, Kos J, Kaur K, Safaei T, Sutanto C, Chen W, et al. Natural killer cells: diverse functions in tumor immunity and defects in pre-neoplastic and neoplastic stages of tumorigenesis. Mol Ther Oncolytics. 2020;16:41\u201352.","journal-title":"Mol Ther Oncolytics"},{"key":"7986_CR32","doi-asserted-by":"publisher","first-page":"1606.","DOI":"10.3389\/fimmu.2017.01606","volume":"8","author":"K Kaur","year":"2017","unstructured":"Kaur K, Chang H-H, Cook J, Eibl G, Jewett A. Suppression of gingival NK cells in precancerous and cancerous stages of pancreatic cancer in KC and BLT-humanized mice. Front Immunol. 2017;8:1606.","journal-title":"Front Immunol"},{"key":"7986_CR33","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2741\/4489","volume":"22","author":"AK Kozlowska","year":"2017","unstructured":"Kozlowska AK, Kaur K, Topchyan P, Jewett A. Novel strategies to target cancer stem cells by NK cells; studies in humanized mice. Front Biosci. 2017;22:370\u201384.","journal-title":"Front Biosci."},{"key":"7986_CR34","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00262-016-1822-9","volume":"65","author":"AK Kozlowska","year":"2016","unstructured":"Kozlowska AK, Kaur K, Topchyan P, Jewett A. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice. Cancer Immunol Immunother. 2016;65:835\u201345.","journal-title":"Cancer Immunol Immunother"},{"key":"7986_CR35","doi-asserted-by":"crossref","unstructured":"Breznik B, Novak M, Majc B, Habi\u010d A, Jewett A. Chapter 16 - Natural killer cells in the treatment of glioblastoma: diverse antitumor functions and potential clinical applications. In: Jewett A, Fong Y, editors. NK Cells in cancer immunotherapy: successes and challenges. Academic; 2023. pp. 335\u201367.","DOI":"10.1016\/B978-0-12-822620-9.00003-3"},{"key":"7986_CR36","doi-asserted-by":"publisher","first-page":"ii39","DOI":"10.1093\/neuonc\/noac174.131","volume":"24","author":"B Breznik","year":"2022","unstructured":"Breznik B, Ko M, Chen P, Senjor E, Majc B, Novak M, et al. P06.07.A natural killer cells lyse glioblastoma stem cells and increase their sensitivity to chemotherapy. Neuro Oncol. 2022;24:ii39. https:\/\/doi.org\/10.1093\/neuonc\/noac174.131.","journal-title":"Neuro Oncol"},{"key":"7986_CR37","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s42003-022-03402-z","volume":"5","author":"B Breznik","year":"2022","unstructured":"Breznik B, Ko M-W, Tse C, Chen P-C, Senjor E, Majc B, et al. Infiltrating natural killer cells bind, lyse and increase chemotherapy efficacy in glioblastoma stem-like tumorospheres. Commun Biol. 2022;5:436.","journal-title":"Commun Biol"},{"key":"7986_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccell.2017.06.009","volume":"32","author":"A Lopez-Soto","year":"2017","unstructured":"Lopez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of metastasis by NK cells. Cancer cell. 2017;32:135\u201354.","journal-title":"Cancer cell"},{"key":"7986_CR39","doi-asserted-by":"publisher","first-page":"e11590","DOI":"10.1371\/journal.pone.0011590","volume":"5","author":"HC Tseng","year":"2010","unstructured":"Tseng HC, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, et al. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS ONE. 2010;5:e11590.","journal-title":"PLoS ONE"},{"key":"7986_CR40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fimmu.2014.00269","volume":"5","author":"HC Tseng","year":"2014","unstructured":"Tseng HC, Bui V, Man YG, Cacalano N, Jewett A. Induction of split anergy conditions natural killer cells to promote differentiation of stem cells through cell-cell contact and secreted factors. Front Immunol. 2014;5:269.","journal-title":"Front Immunol"},{"key":"7986_CR41","doi-asserted-by":"publisher","first-page":"8947","DOI":"10.18632\/oncotarget.3250","volume":"6","author":"HC Tseng","year":"2015","unstructured":"Tseng HC, Cacalano N, Jewett A. Split anergized natural killer cells halt inflammation by inducing stem cell differentiation, resistance to NK cell cytotoxicity and prevention of cytokine and chemokine secretion. Oncotarget. 2015;6:8947\u201359.","journal-title":"Oncotarget"},{"key":"7986_CR42","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10620-010-1340-0","volume":"56","author":"Z Du","year":"2011","unstructured":"Du Z, Qin R, Wei C, Wang M, Shi C, Tian R, et al. Pancreatic cancer cells resistant to chemoradiotherapy rich in \u201cstem-cell-like\u201d tumor cells. Dig Dis Sci. 2011;56:741\u201350.","journal-title":"Dig Dis Sci"},{"key":"7986_CR43","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1245\/s10434-007-9583-5","volume":"14","author":"AN Shah","year":"2007","unstructured":"Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 2007;14:3629\u201337.","journal-title":"Ann Surg Oncol"},{"key":"7986_CR44","first-page":"765","volume":"50","author":"Z Wang","year":"2009","unstructured":"Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of notch signaling pathway. Proc Am Assoc Cancer Res Annu Meet. 2009;50:765\u20136.","journal-title":"Proc Am Assoc Cancer Res Annu Meet"},{"key":"7986_CR45","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1158\/0008-5472.CAN-06-2030","volume":"67","author":"C Li","year":"2007","unstructured":"Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030\u20137.","journal-title":"Cancer Res"},{"key":"7986_CR46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-1-59745-280-9_10","volume":"568","author":"C Li","year":"2009","unstructured":"Li C, Lee CJ, Simeone DM. Identification of human pancreatic cancer stem cells. Methods Mol Biol. 2009;568:161\u201373.","journal-title":"Methods Mol Biol"},{"key":"7986_CR47","doi-asserted-by":"publisher","first-page":"14520","DOI":"10.1074\/jbc.M113.532887","volume":"289","author":"B Bao","year":"2014","unstructured":"Bao B, Azmi AS, Aboukameel A, Ahmad A, Bolling-Fischer A, Sethi S, et al. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1. J Biol Chem. 2014;289:14520\u201333.","journal-title":"J Biol Chem"},{"key":"7986_CR48","first-page":"271","volume":"10","author":"M Safari","year":"2015","unstructured":"Safari M, Khoshnevisan A. Cancer stem cells and chemoresistance in glioblastoma multiform: a review article. J Stem Cells. 2015;10:271\u201385.","journal-title":"J Stem Cells"},{"key":"7986_CR49","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1158\/1541-7786.MCR-08-0409","volume":"7","author":"M Ropolo","year":"2009","unstructured":"Ropolo M, Daga A, Griffero F, Foresta M, Casartelli G, Zunino A, et al. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res. 2009;7:383\u201392.","journal-title":"Mol Cancer Res"},{"key":"7986_CR50","doi-asserted-by":"publisher","first-page":"593","DOI":"10.18632\/oncotarget.5477","volume":"7","author":"N Podergajs","year":"2016","unstructured":"Podergajs N, Motaln H, Raj\u010devi\u0107 U, Verbov\u0161ek U, Kor\u0161i\u010d M, Obad N, et al. Transmembrane protein CD9 is glioblastoma biomarker, relevant for maintenance of glioblastoma stem cells. Oncotarget. 2016;7:593\u2013609.","journal-title":"Oncotarget"},{"key":"7986_CR51","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1101\/gad.324301.119","volume":"33","author":"RC Gimple","year":"2019","unstructured":"Gimple RC, Bhargava S, Dixit D, Rich JN. Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. Genes Dev. 2019;33:591\u2013609.","journal-title":"Genes Dev"},{"key":"7986_CR52","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00262-016-1866-x","volume":"65","author":"AK Kozlowska","year":"2016","unstructured":"Kozlowska AK, Tseng H-C, Kaur K, Topchyan P, Inagaki A, Bui VT, et al. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-\u03b3 after differentiation of glioblastoma by human natural killer cells. Cancer Immunol Immunother. 2016;65:1085\u201397.","journal-title":"Cancer Immunol Immunother"},{"key":"7986_CR53","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7150\/jca.5519","volume":"4","author":"A Jewett","year":"2013","unstructured":"Jewett A, Man YG, Tseng HC. Dual functions of natural killer cells in selection and differentiation of stem cells; role in regulation of inflammation and regeneration of tissues. J Cancer. 2013;4:12\u201324.","journal-title":"J Cancer"},{"key":"7986_CR54","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","volume":"23","author":"LL Lanier","year":"2005","unstructured":"Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225\u201374.","journal-title":"Annu Rev Immunol"},{"key":"7986_CR55","doi-asserted-by":"publisher","first-page":"e000618","DOI":"10.1136\/bmjonc-2024-000618","volume":"4","author":"S Huerta-Yepez","year":"2025","unstructured":"Huerta-Yepez S, Chen PC, Kaur K, Jain Y, Singh T, Esedebe F, et al. Supercharged NK cells, unlike primary activated NK cells, effectively target ovarian cancer cells irrespective of MHC-class I expression. BMJ Oncol. 2025;4:e000618.","journal-title":"BMJ Oncol"},{"key":"7986_CR56","doi-asserted-by":"publisher","first-page":"907","DOI":"10.4049\/jimmunol.156.3.907","volume":"156","author":"A Jewett","year":"1996","unstructured":"Jewett A, Bonavida B. Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol. 1996;156:907\u201315.","journal-title":"J Immunol"},{"key":"7986_CR57","doi-asserted-by":"publisher","first-page":"269.","DOI":"10.3389\/fimmu.2014.00269","volume":"5","author":"H-C Tseng","year":"2014","unstructured":"Tseng H-C, Bui V, Man Y-G, Cacalano N, Jewett A. Induction of split anergy conditions natural killer cells to promote differentiation of stem cells through cell-cell contact and secreted factors. Front Immunol. 2014;5:269.","journal-title":"Front Immunol"},{"key":"7986_CR58","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41419-024-06976-0","volume":"15","author":"L Co\u00ebnon","year":"2024","unstructured":"Co\u00ebnon L, Geindreau M, Ghiringhelli F, Villalba M, Bruchard M. Natural killer cells at the frontline in the fight against cancer. Cell Death Dis. 2024;15:614.","journal-title":"Cell Death Dis"},{"key":"7986_CR59","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/cells14020090","volume":"14","author":"K Kaur","year":"2025","unstructured":"Kaur K, Celis AP, Jewett A. Natural killer cell-secreted IFN-\u03b3 and TNF-\u03b1 mediated differentiation in lung stem-like tumors, leading to the susceptibility of the tumors to chemotherapeutic Drugs. Cells. 2025;14:90.","journal-title":"Cells"},{"key":"7986_CR60","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/JLB.MR0718-299R","volume":"105","author":"F Antonangeli","year":"2019","unstructured":"Antonangeli F, Zingoni A, Soriani A, Santoni A. Senescent cells: living or dying is a matter of NK cells. J Leukoc Biol. 2019;105:1275\u201383.","journal-title":"J Leukoc Biol"},{"key":"7986_CR61","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1189\/jlb.0611308","volume":"91","author":"R Wang","year":"2012","unstructured":"Wang R, Jaw JJ, Stutzman NC, Zou Z, Sun PD. Natural killer cell-produced IFN-\u03b3 and TNF-\u03b1 induce target cell cytolysis through up-regulation of ICAM-1. J Leukoc Biol. 2012;91:299\u2013309.","journal-title":"J Leukoc Biol"},{"key":"7986_CR62","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1172\/JCI115306","volume":"88","author":"LJ Levitt","year":"1991","unstructured":"Levitt LJ, Nagler A, Lee F, Abrams J, Shatsky M, Thompson D. Production of granulocyte\/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor. J Clin Invest. 1991;88:67\u201375.","journal-title":"J Clin Invest"},{"key":"7986_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.619195","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, Guan D, Huo J, Biswas SK, Huang Y, Yang Y, et al. IL-10 enhances human natural killer cell effector functions via metabolic reprogramming regulated by mTORC1 signaling. Front Immunol. 2021;12:619195.","journal-title":"Front Immunol"},{"key":"7986_CR64","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.imlet.2013.12.009","volume":"161","author":"F Bellora","year":"2014","unstructured":"Bellora F, Castriconi R, Dondero A, Carrega P, Mantovani A, Ferlazzo G, et al. Human NK cells and NK receptors. Immunol Lett. 2014;161:168\u201373.","journal-title":"Immunol Lett"},{"key":"7986_CR65","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503\u201310.","journal-title":"Nat Immunol"},{"key":"7986_CR66","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-94-017-9487-9_2","volume":"841","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Zhang Y, Gu W, Sun B. TH1\/TH2 cell differentiation and molecular signals. Adv Exp Med Biol. 2014;841:15\u201344.","journal-title":"Adv Exp Med Biol"},{"key":"7986_CR67","first-page":"000676.","volume":"4","author":"MW Ko","year":"2025","unstructured":"Ko MW, Mei A, Senjor E, Nanut MP, Gao LW, Wong P, et al. Osteoclast-expanded\u00ffsupercharged NK cells perform superior antitumour effector functions. BMJ Oncol. 2025;4:000676.","journal-title":"BMJ Oncol"},{"key":"7986_CR68","doi-asserted-by":"publisher","first-page":"866","DOI":"10.7150\/jca.11527","volume":"6","author":"HC Tseng","year":"2015","unstructured":"Tseng HC, Inagaki A, Bui VT, Cacalano N, Kasahara N, Man YG, et al. Differential targeting of stem cells and differentiated glioblastomas by NK cells. J Cancer. 2015;6:866\u201376.","journal-title":"J Cancer"},{"key":"7986_CR69","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3389\/fimmu.2015.00576","volume":"6","author":"VT Bui","year":"2015","unstructured":"Bui VT, Tseng HC, Kozlowska A, Maung PO, Kaur K, Topchyan P, et al. Augmented IFN-gamma and TNF-alpha induced by probiotic bacteria in NK cells mediate differentiation of stem-like tumors leading to inhibition of tumor growth and reduction in inflammatory cytokine release; regulation by IL-10. Front Immunol. 2015;6:576.","journal-title":"Front Immunol"},{"key":"7986_CR70","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.4049\/jimmunol.159.10.4815","volume":"159","author":"A Jewett","year":"1997","unstructured":"Jewett A, Cavalcanti M, Bonavida B. Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells. J Immunol. 1997;159:4815\u201322.","journal-title":"J Immunol"},{"key":"7986_CR71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/BF01489488","volume":"15","author":"A Jewett","year":"1995","unstructured":"Jewett A, Bonavida B. Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. J Clin Immunol. 1995;15:35\u201344.","journal-title":"J Clin Immunol"},{"key":"7986_CR72","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0198-8859(03)00039-9","volume":"64","author":"A Jewett","year":"2003","unstructured":"Jewett A, Wang MY, Teruel A, Poupak Z, Bostanian Z, Park NH. Cytokine dependent inverse regulation of CD54 (ICAM1) and major histocompatibility complex class I antigens by nuclear factor kappaB in HEp2 tumor cell line: effect on the function of natural killer cells. Hum Immunol. 2003;64:505\u201320.","journal-title":"Hum Immunol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07986-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07986-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07986-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:27:50Z","timestamp":1756902470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07986-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7986"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07986-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"We confirm that methods were approved in accordance with the relevant guidelines and regulations approved by the UCLA Institutional Review Board (IRB#11-00781). Written informed consents, approved by the UCLA Institutional Review Board (IRB#11-00781), were obtained from healthy individuals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"665"}}